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Introduction
Interferons (IFNs) are a family of cytokines participating in in nate immunity against a wide range of viruses and other microbial pathogens.1 IFNs also have anti tumour activities due to their anti proliferative, immunoregulatory and apopto tic properties.2 The effects of IFNs are largely mediated through proteins encoded by IFN stimulated genes (ISGs). One well studied ISG is RNase L, which is one of the key en zymes in the IFN induced 2 SA system. 3 The 2 SA system con sists of two types of enzymes: 2 SA synthetases and RNase L. 4
IFNs induce a family of 2 SA synthetase genes. The 2 SA syn thetases require double stranded RNA (dsRNA) for their activ ities. After activation by dsRNA which is frequently produced during viral infection, 2 SA synthetases convert ATP molecules to pyrophosphate (ppi) and a series of unique, 5' phosphory lated, 2' 5' linked oligoadenylates known as 2 SA with the gen era! formula ppp(A2'p5')nA (n ;;;, 2). 2 SA binds RNase L with high affinity, converting it from its inactive, monomeric state to a potent dimeric endoribonuclease, resulting in degradation of single stranded viral and cellular RNAs. The 2 SA system mediates host defence against certain types of viruses. The overexpression of RNase L in NIH 3T3 cells markedly enhances the antiviral function of IFN, whereas the dominant negative RNase L suppresses the antiviral activity of IFN in SVT2 cells. 5, 6 Mice containing homozygous disruption of the RNase L gene succumbs to encephalomyocarditis (EMCV) infection more rapidly than infected wild type mice.
7 A broad range of viruses including HIV 1, vaccinia virus, human parainfluenza virus 3, vesicular stomatitis virus, and EMCV have shown to be inhib ited in RNase L overexpressing cell lines. 8 RNase L has been linked to apoptosis in response to viral and non viral agents. RNase L null mice show enlarged thy mus glands at early ages, suggesting that RNase L may be in volved in T cell development. In situ assays for DNA fragmentation on tissue sections from both the thymus and spleen reveal a reduction in apoptosis in the untreated RNase L / mice compared to the cognate wild type mice. 7 The direct activation of RNase L by introducing 2 5A into intact cells leads to apoptosis, whereas a dominant negative RNase L de creases the numbers of apoptotic cells generated by poliovi rus infection, IFN and poly (I):poly (C) as well as staurosporine treatments. 9-11 A recent study revealed that RNase L mediates virus induced apoptosis through activating c Jun NH 2 terminal kinase (JNK).
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The evidence has shown that RNase L plays a role in cancer biology. The ARG462GLN variant of RNase L, which has an attenuated enzymatic activity, is implicated in up to 13% of prostate cancer cases. Individuals heterozygous for these mutations exhibit a 150% increased risk of prostate cancer, and homozygotes have greater than double of the risk, under scoring the importance of inactivating RNase L in the etiology of prostate cancer. [13] [14] [15] [16] The inhibitory effect of RNase L on tu mour formation is believed to be due in part to its anti prolif erative and pro apoptotic roles. However, no spontaneous tumour formation has been observed in one year old RNase L / mice. The effect of RNase L on tumourigenesis induced by carcinogens is under investigation in our laboratory. Previ ously we have reported that the overexpression of RNase L in murine NIH 3T3 cells increased IFN anti proliferative func tion. 5 In this study, we have found that bone marrow cells defi cient in RNase L grew significantly faster compared to wild type cells in response to granulate macrophage colony stimu lating factor (GM CSF), suggesting that RNase L regulates cell proliferation stimulated by other growth factors. To determine the direct impact of RNase L on tumour growth in the absence of IFN induced proteins, we have stably expressed RNase L in P 57 cells, an aggressive mouse fibrosarcoma cell line. To as sess the effect of RNase L expression on the ability of p 57 cells to form tumours, these cells were implanted in athymic mice. Results showed that tumour formation was significantly de layed and the tumours grew much slower in the group with RNase L (P RL) compared to the control group (P Vec). Our find ings suggest that RNase L plays a critical role in the inhibition of fibrosarcoma growth in nude mice. supplemented with 10% foetal bovine serum and 10 ng/ml murine GM CSF.
Materials and methods

Cell culture
Overexpression of human RNase L in P-57 Cells
Murine fibrosarcoma cells (P 57) were transfected using Lipo factamine reagent (Invitrogen), with a mammalian expres sion vector, pcDNAneo (Invitrogen), inserted with or without human RNase L cDNA. The cells were selected in the medium containing G418 at 300 lg/ml. Twenty drug resistant clones transfected with the human RNase L cDNA were isolated and analysed for RNase L expression by Western blot analysis. The clonal cell lines containing the vector with RNase L insert or an empty vector are referred to as P RL and P Vec, respectively.
Western blot analysis
Cells were harvested by washing twice with ice cold phos phate buffered saline (PBS) and collected with a scraper. Cyto plasmic extracts were prepared by the suspension of cell pellets in NP 40 lysis buffer (10 mM Tris HCl, pH 8.0, 5 mM Mg(OAc) 2 , 90 mM KCl, 0.2 mM PMSF, 100 U/ml aprotinin, 10 lg/ml leupeptin and 2% NP 40). After centrifugation at 10,000g in a microcentrifuge at 4°C for 10 min, cell extracts (100 lg per sample) were fractionated on SDS 10% polyacryl amide gels and transferred to PVDF membranes (Millipore). The membranes were blocked with 5% non fat milk in PBS containing 0.02% sodium azide and 0.2% (v/v) Tween 20, and incubated with a monoclonal antibody against human RNase L for 1 h at room temperature. The membranes were then washed with PBS containing 0.2% (v/v) Tween 20 and incu bated with goat antimouse antibody conjugated with horse radish peroxidase (Cell Signaling) for 1 h at room temperature. After washing, RNase L was detected by a chemiluminescence method according to the manufacturer's specification (Amersham).
Assay for cell proliferation
RNase L +/+ and / MEFs, P Vec and P RL cells (3 · 10 4 ) were seeded in 6 well plates, and after 1 d, they were treated with or without 1000 U/ml of murine IFN a (Biosource). rule out clonal variation as the cause of the anti tumour ef fect, we separately implanted groups of four mice with two other clones of P RL cells. The tumour results obtained from the different clones of P RL cells (data not shown) were simi lar to that from the first clone used for the experiment, thus eliminating clonal differences as the basis for the anti tu mour activity of RNase L. Microscopically, the P Vec tumours demonstrated a uni form herringbone growth pattern consisting of spindle shaped cells that varied little in size and shape and had scant cytoplasm with indistinct cell borders (Fig. 5a ). Inter estingly, dramatic differences in morphology were observed in P RL tumours (Fig. 5b) , which had a less distinct fascicular or herringbone pattern. The tumour cells were epithelioid with large round and polygonal cells, open chromatin, and prominent central nucleoi. They also showed prominent pleomorphism with variable cell shape and nuclear size. This morphologic difference resembled that of the cultured cells (Fig. 3a) .
P-RL tumour growth is due to suppression of RNase L expression
It was possible that P RL tumours started to grow eventually in the nude mice were due to the suppression of RNase L expression by an unknown mechanism. To determine RNase L level in the tumour cells, RNase L in P RL tumours was mea sured by Western blot analysis in tumour extracts using a monoclonal antibody to human RNase L. As shown, the expression of RNase L was completely shut down in the P RL tumours, suggesting that RNase L plays an important role in the inhibition of tumour growth (Fig. 6 ).
Discussion
RNase L has been suggested to function as a tumour suppres sor based on its roles in mediating apoptosis and anti prolif erative activity of IFN. 18 Our findings provide the first direct evidence that RNase L is able to inhibit tumour growth produces an enhanced anti proliferative effect on MEFs, RNase L is able to inhibit cell proliferation independent of IFN (Fig. 1a) . In addition, RNase L also regulates the growth of bone marrow cells in the presence of GM CSF, suggesting a broader role of RNase L in mediating cell proliferation (Fig. 1b) . Surprisingly, we found that the overexpression of RNase L suppressed the tumour cell growth although there was no significant difference between P RL and P Vec cells in response to IFN (Fig. 2b) . The expression of RNase L is cell specific. The expression level of RNase L in certain cell types such as B cells, lymphoblasts, myelobasts and monocytes is about 20 30 fold higher than that in fibroblasts (our unpub lished data). How these cells survive with the extremely high level of RNase L remains to be investigated. RNase L is believed to display its biological function through regulating mRNA stability after IFN treatment. Ribo somal and viral RNAs have been the first reported targets of RNase L. Documented evidence has shown that RNase L plays an important role in the stability of several gene products, including IFN induced genes, such as ISG43, ISG15 19 and PKR 20 in RNase L null cells; MyoD mRNA in myocytes 21 and mitochondrial mRNAs in H9 lymphocytes. 22 However, in the absence of viral infection, the sources of dsRNA and 2 5A to activate 2 5A synthetase, and RNase L remain obscure. It is possible that RNase L can indirectly regulate gene expression through interacting with other proteins because RNase L con tains structurally nine ankyrin repeats, a typical protein pro tein interaction domain. Recently, Peltz's group has demonstrated that RNase L is indeed able to regulate gene expression by interacting with another protein. 23 They dis covered that RNase L can interact with human translation ter mination factor eRF3/GSPT1 to modulate the translation termination process, resulting in regulating gene expression. Their results outline a novel role for RNase L as a regulator of translation.
The effect of RNase L on cell growth was not obvious when cells were grown at a low density (Fig. 3a) . However, when cells grew at a high density, the morphological difference be tween these two cell lines was dramatic. P Vec cells grew more aggressively. Even though the cells have grown to con fluence, P Vec cells continued to grow, and piled up to form individual clones if fresh medium was provided. P RL cells ceased growing after cells became confluent. These cells were large and had a polygonal shape, probably due in part to the altered cell morphology. Furthermore, anchorage indepen dent growth in soft agar (Fig. 3b) is consistent with the obser vation in tumour formation in nude mice (Fig. 4a) . These findings indicate a role of RNase L in suppressing tumour growth. Surprisingly, no spontaneous tumour formation has been observed in one year old RNase L / mice. Currently, the effect of RNase on tumourigenesis induced by carcino gens is under investigation in our laboratory. We are also cross breeding RNase L overexpression of RNase L may affect JNK regulated cytoskel etal molecules, and therefore cause the morphological alter ation. Interestingly, increased single cell necrosis was observed in P RL tumours. Whether the increased cell death is due to the overexpression of RNase L promoting apoptosis needs to be further investigated.
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